NCT02365597 2026-03-19
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Janssen Research & Development, LLC
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT02581137 2026-03-18
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02946996 2026-03-05
Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
Medical University of South Carolina
Phase 2 Terminated
NCT04850846 2026-02-09
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03109847 2025-12-11
Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Thyroid Cancers
Thomas Jefferson University
Phase 2 Terminated
NCT02186847 2025-10-09
Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
NRG Oncology
Phase 2 Completed
NCT02500147 2025-07-02
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
Columbia University
Phase 4 Terminated
NCT03109873 2025-04-30
Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer
Thomas Jefferson University
Phase EARLY_PHASE1 Completed
NCT01905046 2025-04-13
Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting